XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Financial Instruments Recorded at Estimated Fair Value
The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of the assets and liabilities was as follows:
($ in millions)Fair Value Measurement Level March 31, 2025December 31, 2024
Other current assets:
Forward contracts2$15 $29 
Other assets:
Cross-currency swap227 
Accrued and other current liabilities:
Contingent consideration3— 75 
Forward contracts214 13 
Other noncurrent liabilities:
Contingent consideration3330 319 
Schedule of Long-term Debt Instruments
Foreign currency gain (loss) due to spot rate fluctuations on the euro-denominated debt instruments and the change in fair value of the cross-currency swaps resulting from hedge designation were included within Cumulative translation adjustment in Other comprehensive income (loss), net of taxes:

Three Months Ended
March 31,
($ in millions)20252024
Euro-denominated debt instruments (loss) gain
$(70)$49 
Cross-currency swaps loss
(25)— 
Schedule of (Gain) Loss on Derivative Instruments
The Condensed Consolidated Statements of Income include the impact of net (gains) losses of Organon’s derivative financial instruments:
Three Months Ended
March 31,
($ in millions)20252024
Derivative gain in Exchange (gains) losses
$(2)$(1)
Derivative gain in Interest expense
(4)— 
Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following table presents a reconciliation of contingent consideration measured on a recurring basis using significant unobservable inputs (Level 3):
($ in millions)March 31, 2025
Beginning balance $394 
Accretion11 
Payment (75)
Ending balance $330